beta blocker: be contraindicated in peripheral vascular disease

from Quasimodo
0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Related concepts

Parents agent
Weight: 0.65
, high blood pressure
Weight: 0.63
, heart disease
Weight: 0.63
, vasodilator
Weight: 0.62
Siblings atenolol
Weight: 0.53
, lung cancer
Weight: 0.33
, cystic fibrosis
Weight: 0.33
, agonist
Weight: 0.32
, blood clot
Weight: 0.32

Related properties

Property Similarity
be contraindicated in peripheral vascular disease 1.00
be contraindicated in vascular disease 0.98
be contraindicated in peripheral disease 0.97
be contraindicated in disease 0.91
worsen peripheral vascular disease 0.91
be contraindicated in pheochromocytoma 0.90
be contraindicated in myasthenia gravis 0.90
be contraindicated in diabetes mellitus 0.90
be contraindicated in pulmonary edema 0.90
be contraindicated in diabetes 0.90

Priors about this statement

Cues

0.2 0.4 0.6 0.8 Joint Necessity Sufficiency Implication Entailment Contradiction Entropy

Evidence

0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Clauses

Salient implies Plausible

0.19
Rule weight: 0.28
Evidence weight: 0.68
Similarity weight: 1.00
Evidence: 0.59
Plausible(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.78
¬ Salient(beta blocker, be contraindicated in peripheral vascular disease)

Similarity expansion

0.69
Rule weight: 0.85
Evidence weight: 0.90
Similarity weight: 0.90
Evidence: 0.83
Remarkable(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.58
¬ Remarkable(beta blocker, be contraindicated in pheochromocytoma)
0.68
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.90
Evidence: 0.83
Remarkable(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.66
¬ Remarkable(beta blocker, be contraindicated in diabetes)
0.68
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.90
Evidence: 0.83
Remarkable(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated in diabetes mellitus)
0.67
Rule weight: 0.85
Evidence weight: 0.87
Similarity weight: 0.90
Evidence: 0.83
Remarkable(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.75
¬ Remarkable(beta blocker, be contraindicated in pulmonary edema)
0.66
Rule weight: 0.85
Evidence weight: 0.86
Similarity weight: 0.91
Evidence: 0.83
Remarkable(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.85
¬ Remarkable(beta blocker, worsen peripheral vascular disease)
0.66
Rule weight: 0.85
Evidence weight: 0.86
Similarity weight: 0.90
Evidence: 0.83
Remarkable(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.86
¬ Remarkable(beta blocker, be contraindicated in myasthenia gravis)
0.65
Rule weight: 0.85
Evidence weight: 0.84
Similarity weight: 0.91
Evidence: 0.78
Salient(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.74
¬ Salient(beta blocker, worsen peripheral vascular disease)
0.65
Rule weight: 0.85
Evidence weight: 0.84
Similarity weight: 0.90
Evidence: 0.78
Salient(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.72
¬ Salient(beta blocker, be contraindicated in myasthenia gravis)
0.64
Rule weight: 0.85
Evidence weight: 0.84
Similarity weight: 0.90
Evidence: 0.78
Salient(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.74
¬ Salient(beta blocker, be contraindicated in pulmonary edema)
0.63
Rule weight: 0.85
Evidence weight: 0.82
Similarity weight: 0.90
Evidence: 0.78
Salient(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.84
¬ Salient(beta blocker, be contraindicated in pheochromocytoma)
0.62
Rule weight: 0.85
Evidence weight: 0.82
Similarity weight: 0.90
Evidence: 0.78
Salient(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.85
¬ Salient(beta blocker, be contraindicated in diabetes)
0.62
Rule weight: 0.85
Evidence weight: 0.81
Similarity weight: 0.90
Evidence: 0.52
Typical(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.40
¬ Typical(beta blocker, be contraindicated in myasthenia gravis)
0.62
Rule weight: 0.85
Evidence weight: 0.81
Similarity weight: 0.90
Evidence: 0.78
Salient(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.87
¬ Salient(beta blocker, be contraindicated in diabetes mellitus)
0.61
Rule weight: 0.85
Evidence weight: 0.79
Similarity weight: 0.91
Evidence: 0.52
Typical(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.43
¬ Typical(beta blocker, worsen peripheral vascular disease)
0.61
Rule weight: 0.85
Evidence weight: 0.79
Similarity weight: 0.90
Evidence: 0.59
Plausible(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.51
¬ Plausible(beta blocker, be contraindicated in myasthenia gravis)
0.61
Rule weight: 0.85
Evidence weight: 0.78
Similarity weight: 0.91
Evidence: 0.59
Plausible(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.53
¬ Plausible(beta blocker, worsen peripheral vascular disease)
0.58
Rule weight: 0.85
Evidence weight: 0.76
Similarity weight: 0.90
Evidence: 0.59
Plausible(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.60
¬ Plausible(beta blocker, be contraindicated in pulmonary edema)
0.55
Rule weight: 0.85
Evidence weight: 0.72
Similarity weight: 0.90
Evidence: 0.52
Typical(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.58
¬ Typical(beta blocker, be contraindicated in pulmonary edema)
0.53
Rule weight: 0.85
Evidence weight: 0.69
Similarity weight: 0.90
Evidence: 0.59
Plausible(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.76
¬ Plausible(beta blocker, be contraindicated in diabetes)
0.52
Rule weight: 0.85
Evidence weight: 0.68
Similarity weight: 0.90
Evidence: 0.59
Plausible(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.79
¬ Plausible(beta blocker, be contraindicated in pheochromocytoma)
0.52
Rule weight: 0.85
Evidence weight: 0.68
Similarity weight: 0.90
Evidence: 0.59
Plausible(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.78
¬ Plausible(beta blocker, be contraindicated in diabetes mellitus)
0.47
Rule weight: 0.85
Evidence weight: 0.62
Similarity weight: 0.90
Evidence: 0.52
Typical(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.80
¬ Typical(beta blocker, be contraindicated in diabetes)
0.47
Rule weight: 0.85
Evidence weight: 0.61
Similarity weight: 0.90
Evidence: 0.52
Typical(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.81
¬ Typical(beta blocker, be contraindicated in diabetes mellitus)
0.46
Rule weight: 0.85
Evidence weight: 0.59
Similarity weight: 0.90
Evidence: 0.52
Typical(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.85
¬ Typical(beta blocker, be contraindicated in pheochromocytoma)

Typical and Remarkable implies Salient

0.13
Rule weight: 0.14
Evidence weight: 0.91
Similarity weight: 1.00
Evidence: 0.78
Salient(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.52
¬ Typical(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.83
¬ Remarkable(beta blocker, be contraindicated in peripheral vascular disease)

Typical implies Plausible

0.38
Rule weight: 0.48
Evidence weight: 0.79
Similarity weight: 1.00
Evidence: 0.59
Plausible(beta blocker, be contraindicated in peripheral vascular disease) ⋁
Evidence: 0.52
¬ Typical(beta blocker, be contraindicated in peripheral vascular disease)